Vertex Gains In Vivo CRISPR Foothold With Mammoth Pact
Deal Snapshot: The nearly $700m deal gives Vertex, already with a major foothold in CRISPR, access to Mammoth’s ultra-compact gene-editing technology in two diseases.
You may also be interested in...
Deal Watch: Merck Looks To Technology Platform Partners For Cytokine Agonist Discovery, Drug Delivery
Plus deals involving Moderna/Metagenomi, Agomab/Origo, Selecta/Ginkgo, Teva/MODAG, Boehringer Ingelheim/Thoeris and X-Chem/ComInnex/Glamorous AI.
Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.
The first use of CRISPR/Cas9 in humans shows promising safety and efficacy against rare disease ATTR, and opens up the possibility of treating many genetic diseases.